Last Price$94.32.5%
Market Cap$120.9B
LTM Depreciation & Amortization (D&A)
$2,675.0M
YoY Growth
+0.1%
3Y CAGR
-0.3%
5Y CAGR
+0.1%
Stock quality & Intrinsic value
6/10
21.5% undervalued
Medtronic plc Depreciation & Amortization (D&A)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Apr'05 | Apr'06 | Apr'07 | Apr'08 | Apr'09 | Apr'10 | Apr'11 | Apr'12 | Apr'13 | Apr'14 | Apr'15 | Apr'16 | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Depreciation & Amortization (D&A) | $463.3M | $543.6M | $583.0M | $637.0M | $699.0M | $772.0M | $804.0M | $862.0M | $819.0M | $850.0M | $1,306.0M | $2,820.0M | $2,917.0M | $2,644.0M | $2,659.0M | $2,663.0M | $2,702.0M | $2,707.0M | $2,697.0M | $2,647.0M |
Overvalued or undervalued?
Check the intrinsic value for MDT
and see if it's the right time to invest.
Medtronic plc (MDT) Depreciation & Amortization (D&A) comparison analysis
General
LTM Depreciation & Amortization (D&A)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Medtronic plcMDT
$2,675.0M
0.1%
(0.3%)
0.1%
Median Peer Set
$154.6M
3.1%
2.8%
7.9%
Abbott LaboratoriesABT
$3,218.0M
(0.8%)
(3.1%)
1.3%
Boston Scientific CorporationBSX
$1,599.0M
33.7%
13.5%
9.6%
Stryker CorporationSYK
$1,050.0M
2.1%
2.0%
6.2%
Zimmer Biomet Holdings, Inc.ZBH
$996.3M
4.7%
(2.3%)
(0.2%)
DexCom, Inc.DXCM
$159.9M
(14.0%)
16.2%
26.8%
Edwards Lifesciences CorporationEW
$149.3M
4.0%
3.6%
11.8%
Align Technology, Inc.ALGN
$145.0M
31.5%
10.1%
12.9%
STERIS plcSTE
$134.4M
(66.5%)
(29.2%)
(7.3%)
Insulet CorporationPODD
$80.8M
11.0%
12.1%
23.7%
Koninklijke Philips N.V.PHG
$0.0
N/A
N/A
N/A
MDT key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Apr'05 | Apr'06 | Apr'07 | Apr'08 | Apr'09 | Apr'10 | Apr'11 | Apr'12 | Apr'13 | Apr'14 | Apr'15 | Apr'16 | Apr'17 | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 10,054.6 10.6% | 11,292.0 12.3% | 12,299.0 8.9% | 13,515.0 9.9% | 14,599.0 8.0% | 15,817.0 8.3% | 15,933.0 0.7% | 16,184.0 1.6% | 16,590.0 2.5% | 17,005.0 2.5% | 20,261.0 19.1% | 28,833.0 42.3% | 29,710.0 3.0% | 29,953.0 0.8% | 30,557.0 2.0% | 28,913.0 (5.4%) | 30,117.0 4.2% | 31,686.0 5.2% | 31,227.0 (1.4%) | 32,364.0 3.6% |
| Cost of Goods Sold (COGS) | 2,446.4 | 2,815.3 | 3,168.0 | 3,446.0 | 3,518.0 | 3,812.0 | 3,912.0 | 3,889.0 | 4,126.0 | 4,333.0 | 6,309.0 | 9,142.0 | 9,291.0 | 9,055.0 | 9,155.0 | 9,424.0 | 10,483.0 | 10,145.0 | 10,719.0 | 11,216.0 |
% margin | 7,608.2 75.7% | 8,476.7 75.1% | 9,131.0 74.2% | 10,069.0 74.5% | 11,081.0 75.9% | 12,005.0 75.9% | 12,021.0 75.4% | 12,295.0 76.0% | 12,464.0 75.1% | 12,672.0 74.5% | 13,952.0 68.9% | 19,691.0 68.3% | 20,419.0 68.7% | 20,898.0 69.8% | 21,402.0 70.0% | 19,489.0 67.4% | 19,634.0 65.2% | 21,541.0 68.0% | 20,508.0 65.7% | 21,148.0 65.3% |
| Operating Expenses | 4,164.9 | 4,772.3 | 5,392.0 | 5,982.0 | 6,903.0 | 7,740.0 | 7,041.0 | 7,899.0 | 7,694.0 | 7,854.0 | 9,395.0 | 13,731.0 | 14,106.0 | 14,555.0 | 14,770.0 | 14,267.0 | 14,739.0 | 15,633.0 | 14,678.0 | 16,129.0 |
| Research & Development Expenses (R&D) | 951.3 | 1,112.9 | 1,239.0 | 1,275.0 | 1,355.0 | 1,483.0 | 1,508.0 | 1,490.0 | 1,557.0 | 1,477.0 | 1,640.0 | 2,224.0 | 2,193.0 | 2,253.0 | 2,330.0 | 2,331.0 | 2,493.0 | 2,746.0 | 2,696.0 | 2,735.0 |
| Selling, General & Administrative Expenses (SG&A) | 3,213.6 | 3,659.4 | 4,153.0 | 4,707.0 | 5,152.0 | 5,789.0 | 5,533.0 | 6,074.0 | 5,698.0 | 5,847.0 | 6,904.0 | 9,469.0 | 9,711.0 | 9,974.0 | 10,418.0 | 10,109.0 | 10,148.0 | 10,292.0 | 10,415.0 | 10,736.0 |
% margin | 2,543.5 25.3% | 3,161.3 28.0% | 3,515.0 28.6% | 2,885.0 21.3% | 2,811.0 19.3% | 4,371.0 27.6% | 4,173.0 26.2% | 4,696.0 29.0% | 4,639.0 28.0% | 4,084.0 24.0% | 3,766.0 18.6% | 5,291.0 18.4% | 5,330.0 17.9% | 6,651.0 22.2% | 6,268.0 20.5% | 4,791.0 16.6% | 4,484.0 14.9% | 5,752.0 18.2% | 5,485.0 17.6% | 5,144.0 15.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 364.0 | 188.0 | 156.0 | 172.0 | 200.0 | 237.0 | 271.0 | 386.0 | 431.0 | 366.0 | 397.0 | 1,444.0 | 300.0 | 192.0 | 367.0 | 386.0 | 0.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 255.0 | 217.0 | 246.0 | 450.0 | 149.0 | 388.0 | 379.0 | 666.0 | 1,386.0 | 1,094.0 | 1,146.0 | 1,444.0 | 1,092.0 | 925.0 | 553.0 | 636.0 | 719.0 |
| Pre-tax Income | 2,543.5 | 3,161.3 | 3,515.0 | 2,885.0 | 2,594.0 | 3,969.0 | 3,723.0 | 4,145.0 | 4,251.0 | 3,705.0 | 3,486.0 | 4,336.0 | 4,602.0 | 5,675.0 | 5,197.0 | 4,055.0 | 3,895.0 | 5,517.0 | 5,364.0 | 4,837.0 |
% effective tax rate | 739.6 29.1% | 614.6 19.4% | 713.0 20.3% | 654.0 22.7% | 425.0 16.4% | 870.0 21.9% | 627.0 16.8% | 730.0 17.6% | 784.0 18.4% | 640.0 17.3% | 811.0 23.3% | 798.0 18.4% | 578.0 12.6% | 2,580.0 45.5% | 547.0 10.5% | (751.0) (18.5%) | 265.0 6.8% | 456.0 8.3% | 1,580.0 29.5% | 1,133.0 23.4% |
% margin | 1,803.9 17.9% | 2,546.7 22.6% | 2,802.0 22.8% | 2,231.0 16.5% | 2,169.0 14.9% | 3,099.0 19.6% | 3,096.0 19.4% | 3,617.0 22.3% | 3,467.0 20.9% | 3,065.0 18.0% | 2,675.0 13.2% | 3,538.0 12.3% | 4,028.0 13.6% | 3,104.0 10.4% | 4,631.0 15.2% | 4,789.0 16.6% | 3,606.0 12.0% | 5,039.0 15.9% | 3,758.0 12.0% | 3,676.0 11.4% |
| EPS | 1.49 | 2.11 | 2.44 | 1.97 | 1.85 | 2.80 | 2.87 | 3.43 | 3.40 | 3.06 | 2.44 | 2.51 | 2.92 | 2.29 | 3.44 | 3.57 | 2.68 | 3.75 | 2.83 | 2.77 |
| Diluted EPS | 1.48 | 2.09 | 2.41 | 1.95 | 1.84 | 2.79 | 2.86 | 3.41 | 3.37 | 3.02 | 2.41 | 2.48 | 2.89 | 2.27 | 3.41 | 3.54 | 2.66 | 3.73 | 2.82 | 2.76 |
% margin | 3,061.9 30.5% | 4,172.8 37.0% | 4,322.0 35.1% | 3,631.0 26.9% | 3,510.0 24.0% | 5,143.0 32.5% | 5,058.0 31.7% | 5,327.0 32.9% | 5,538.0 33.4% | 5,645.0 33.2% | 6,278.0 31.0% | 8,539.0 29.6% | 9,027.0 30.4% | 9,189.0 30.7% | 9,368.0 30.7% | 7,825.0 27.1% | 8,192.0 27.2% | 9,554.0 30.2% | 8,475.0 27.1% | 8,203.0 25.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Medtronic plc's Depreciation & Amortization (D&A)?
As of today, Medtronic plc's last 12-month Depreciation & Amortization (D&A) is $2,675.0M, based on the financial report for Jan 24, 2025 (Q1’2025).
2) What is Medtronic plc's Depreciation & Amortization (D&A) growth rate?
Over the last year, Medtronic plc's Depreciation & Amortization (D&A) growth was 0.1%. The average annual Depreciation & Amortization (D&A) growth rates for Medtronic plc have been (0.4%) over the past three years, 0.1% over the past five years.
3) Is Medtronic plc's Depreciation & Amortization (D&A) growth rate Good?
Over the last year, Medtronic plc's Depreciation & Amortization (D&A) growth was 0.1%, which is higher than industry growth of 0.0%. It indicates that Medtronic plc's Depreciation & Amortization (D&A) growth is Good.